Tumor targeting using anti-her2 immunoliposomes

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

1986 • 6,585 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2000 • 2,394 citations

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 • 1,867 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

1991 • 1,370 citations

Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

1999 • 1,231 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases

1993 • 883 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 • 667 citations

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

1990 • 640 citations

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

1998 • 628 citations

The Carrier Potential of Liposomes in Biology and Medicine

1976 • 576 citations

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1993 • 501 citations

Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro

1997 • 438 citations

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.

1992 • 422 citations

Liposomes Revisited

1995 • 418 citations

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

1990 • 401 citations

Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site

1996 • 380 citations

Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma

1996 • 370 citations

Stabilization of cationic liposome‐plasmid DNA complexes by polyamines and poly(ethylene glycol)‐phospholipid conjugates for efficient in vivo gene delivery

1997 • 316 citations

Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times

1993 • 284 citations

Development of anti-p185HER2 immunoliposomes for cancer therapy.

1995 • 258 citations

Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides

1998 • 214 citations

Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times

1989 • 210 citations

c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties

1995 • 210 citations

Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay

1990 • 199 citations

Stability of HER-2/neu Expression Over Time and at Multiple Metastatic Sites

1993 • 161 citations

In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library

1995 • 160 citations

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

1994 • 160 citations

Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis

1999 • 158 citations

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

1999 • 133 citations

Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease

1999 • 126 citations

Immunoliposomes for Cancer Treatment

1997 • 116 citations

Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.

1991 • 100 citations

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.

1999 • 99 citations

Genes, oncogenes, and hormones : advances in cellular and molecular biology of breast cancer

1991 • 76 citations

Selection of Potentially Metastatic Subpopulations Expressing c-erbB-2 from Breast Cancer Tissue by Use of an Extravasation Model

1998 • 66 citations

X‐ray structures of fragments from binding and nonbinding versions of a humanized anti‐CD18 antibody: Structural indications of the key role of V_H residues 59 to 65

1994 • 55 citations

Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function

2001 • 54 citations

Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy

1991 • 47 citations

Should HER2 status be routinely measured for all breast cancer patients?

1999 • 35 citations